New BioSymetrics Inc. white paper and executed Master Collaboration Agreement establish an integrated roadmap spanning AI-driven patient stratification, human translational validation, biomarker development, and pharmaceutical partnering.

SACRAMENTO, Calif., and SAN DIEGO, Calif., Aug. 4, 2026 /PRNewswire/ -- Lunai Bioworks Inc. (NASDAQ:LNAI), a biology-first AI drug discovery company, today announced the execution of a Master Collaboration Agreement with BrainStorm Therapeutics Inc. ("BrainStorm"), an AI-powered precision neuroscience company developing disease-modifying therapies using patient-derived human brain organoids and multimodal artificial intelligence.

In parallel, Lunai's wholly owned subsidiary BioSymetrics Inc. ("BioSymetrics"), published a new technical white paper, Phenoclustering Parkinson's Disease to Uncover New Targets and Biomarkers.  The companies are targeting an initial data readout from the collaboration for the first half of 2027.

Together, the agreement and white paper establish an integrated workflow that combines BioSymetrics' patented Contingent AI™ patient-stratification platform with BrainStorm's award-winning familial Parkinson's disease midbrain organoid and AI platform. The collaboration is designed to translate computationally identified patient subtypes into experimentally validated disease mechanisms, biomarkers, therapeutic targets, and partner-ready drug-development opportunities.

The collaboration will be led by a joint scientific working team. An initial Statement of Work is organized around four objectives:

  1. Align clinically defined Parkinson's disease subtypes with underlying biological mechanisms.
  2. Prioritize subtype-associated biomarkers and therapeutic targets.
  3. Test disease mechanisms and therapeutic hypotheses in BrainStorm's patient-derived human midbrain organoids and complementary in vivo systems.
  4. Develop a partner-ready decision package for pharmaceutical and biotechnology collaborators.

The BioSymetrics white paper describes how the company's Contingent AI™ platform analyzed the Parkinson's Progression Markers Initiative (PPMI) dataset to identify clinically distinct Parkinson's disease subtypes associated with fast motor progression, cognitive and neurological decline, and a female-enriched functional progression profile. By linking baseline patient characteristics with longitudinal clinical outcomes and proteomic signatures extending beyond two years, the analysis provides a foundation for precision patient stratification, biomarker discovery, and therapeutic target identification.

BrainStorm will provide the human translational component of the collaboration through its patient-derived familial Parkinson's disease midbrain organoid platform and associated AI foundation-model capabilities. By integrating human genetics, single-cell transcriptomics, functional phenotyping, and artificial intelligence, BrainStorm's platform is designed to identify convergent disease mechanisms shared across rare, genetically defined familial forms of Parkinson's disease and the broader sporadic patient population, and to prioritize disease-modifying therapeutic targets with relevance across these patient groups.

BrainStorm's Parkinson's disease platform has been recognized with the NVIDIA Bio x AI Award, the California Life Sciences Pantheon AI Catalyst Award, and the BioMarin Genetic Explorer Award. By evaluating BioSymetrics' computational findings directly in patient-derived human brain tissue models, the companies aim to address a central challenge in precision neuroscience: determining whether clinically identified patient subtypes reflect distinct and therapeutically actionable biological mechanisms.

Three-Stage Commercial Strategy

The collaboration is designed to generate value across three complementary commercial opportunities.

Near term, Lunai expects its patient-subtype framework to support pharmaceutical partners in improving clinical-trial design, patient selection, and endpoint optimization. More precisely defined patient populations may reduce trial heterogeneity and improve the ability to detect therapeutic efficacy.

Medium term, the companies plan to refine subtype-associated proteomic signatures into deployable biomarker panels. Following further analytical and clinical validation, these panels could support patient inclusion and exclusion criteria, subgroup analyses, treatment-response monitoring, and potential future companion-diagnostic development, subject to regulatory review.

Longer term, BrainStorm's patient-derived midbrain organoids will provide a human-relevant experimental system for testing subtype-specific disease mechanisms and AI-prioritized therapeutic targets. Combined with Lunai's computational and phenotypic-validation capabilities, this work is intended to generate partner-ready therapeutic programs supported by a defined patient population, biomarker strategy, validated biological rationale, and human translational evidence.